CTOs on the Move

The Rose

www.the-rose.org

 
The Rose is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.the-rose.org
  • 12700 N Featherwood Dr Ste 260
    Houston, TX USA 77034
  • Phone: 281.484.6656

Executives

Name Title Contact Details

Similar Companies

CBLPath

CBLPath is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Mitchell Laboratories Inc

Mitchell Laboratories Inc is a Pico Rivera, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BestCare Laboratory Services

BestCare Laboratory Services is a Webster, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paradigm Spine

Paradigm Spine is a provider of non-fusion and fusion spinal implant solutions that serve to address the unmet clinical needs of spine surgeons and their patients. Starting with the coflex® Interlaminar Stabilization® device, Paradigm Spine develops a full non-fusion product portfolio of motion preserving, tissue sparing technologies, as well as fusion products. It is our commitment to lead the positioning of non-fusion technologies to the forefront of improving the quality of life in patients with spinal diseases through being

Gritstone Oncology

Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.